Advertisement
Advertisement
ESLA
Estrella Immunopharma, Inc. Common Stock
1.26
USDSponsored
-0.01
-0.79%
May 08, 15:43 UTC -4
Closed
After-Market
1.21
-0.05
-3.97%
ESLA Earnings Reports
Positive Surprise Ratio
ESLA beat 2 of 4 last estimates.
50%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Estrella Immunopharma, Inc. Common Stock earnings per share and revenue
On Mar 18, 2026, ESLA reported earnings of -0.35 USD per share (EPS) for Q2 26, missing the estimate of -0.18 USD, resulting in a -90.63% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.70% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Estrella Immunopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Estrella Immunopharma, Inc. Common Stock reported EPS of -$0.35, missing estimates by -90.63%, and revenue of --, 0% as expectations.
How did the market react to Estrella Immunopharma, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -2.7%, changed from $1.11 before the earnings release to $1.08 the day after.
When is Estrella Immunopharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Estrella Immunopharma, Inc. Common Stock's next earnings report?
Based on --
analysts, Estrella Immunopharma, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement